Community Acquired Pneumonia Therapeutics
1. Avelox patent expiration
Treatment: Method of combating bacteria in a patient
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6610327 | BAYER HLTHCARE | Pharmaceutical moxifloxacin preparation |
Oct, 2019
(6 years ago) | |
| US5849752 | BAYER HLTHCARE | Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification |
Dec, 2016
(9 years ago) | |
| US5607942 | BAYER HLTHCARE | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Mar, 2014
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-185) | Sep 27, 2019 |
Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 December, 1999
Dosage: TABLET
How can I launch a generic of AVELOX before it's drug patent expiration?
More Information on Dosage
AVELOX family patents
2. Factive patent expiration
Treatment: Method of treating bacterial infections; Use of quinolone compounds against anaerobic pathogenic bacteria; Use of quinolone compounds against pneumococcal pathogenic bacteria; Use of quinolone compoun...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5962468 | LG CHEM LTD | 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1- cyclopropyl-6-fluoro-4-oxo-1, 4-dihydro-1, 8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
Jun, 2015
(10 years ago) | |
| US6455540 | LG CHEM LTD | Methods of use of quinolone compounds against anaerobic pathogenic bacteria |
Sep, 2019
(6 years ago) | |
| US5633262 | LG CHEM LTD | Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituent and processes for preparing thereof |
Jun, 2015
(10 years ago) | |
| US6803376 | LG CHEM LTD | Method of use of quinolone compounds against pneumococcal and haemophilus bacteria |
Sep, 2019
(6 years ago) | |
| US6340689 | LG CHEM LTD | Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria |
Sep, 2019
(6 years ago) | |
| US5776944 | LG CHEM LTD | 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
Apr, 2017
(8 years ago) | |
| US6723734 | LG CHEM LTD | Salt of naphthyridine carboxylic acid derivative |
Mar, 2018
(7 years ago) | |
| US6331550 | LG CHEM LTD | Methods of use of quinolone compounds against anaerobic pathogenic bacteria |
Sep, 2019
(6 years ago) | |
| US6262071 | LG CHEM LTD | Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria |
Sep, 2019
(6 years ago) | |
Drugs and Companies using GEMIFLOXACIN MESYLATE ingredient
Market Authorisation Date: 04 April, 2003
Dosage: TABLET
How can I launch a generic of FACTIVE before it's drug patent expiration?
More Information on Dosage
FACTIVE family patents
3. Invanz patent
expiration
Treatment: Treatment of bacterial infectious disease
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5478820 (Pediatric) | MSD SUB MERCK | Antibiotic compounds |
May, 2016
(9 years ago) | |
| US5652233 | MSD SUB MERCK | Antibiotic compounds |
Feb, 2013
(12 years ago) | |
|
US5952323 (Pediatric) | MSD SUB MERCK | Carbapenem antibiotic |
Nov, 2017
(8 years ago) | |
| US7342005 | MSD SUB MERCK | Antibiotic compounds |
Feb, 2013
(12 years ago) | |
|
US7342005 (Pediatric) | MSD SUB MERCK | Antibiotic compounds |
Aug, 2013
(12 years ago) | |
|
US5652233 (Pediatric) | MSD SUB MERCK | Antibiotic compounds |
Aug, 2013
(12 years ago) | |
| US5478820 | MSD SUB MERCK | Antibiotic compounds |
Nov, 2015
(10 years ago) | |
| US5952323 | MSD SUB MERCK | Carbapenem antibiotic |
May, 2017
(8 years ago) | |
Drugs and Companies using ERTAPENEM SODIUM ingredient
Market Authorisation Date: 21 November, 2001
Dosage: INJECTABLE
How can I launch a generic of INVANZ before it's drug patent expiration?
More Information on Dosage
INVANZ family patents
4. Ketek patent expiration
Treatment: Treatment of community acquired pneumonia, acute exacerbation of chronic bronchitis, and acute bacterial sinusitis caused by susceptible str...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USD459798 | SANOFI AVENTIS US | Pill tablet |
Sep, 2015
(10 years ago) | |
| US5635485 | SANOFI AVENTIS US | Erythromycin compounds |
Apr, 2018
(7 years ago) | |
Drugs and Companies using TELITHROMYCIN ingredient
Market Authorisation Date: 01 April, 2004
Dosage: TABLET
More Information on Dosage
KETEK family patents
5. Nuzyra patent expiration
Treatment: Treatment of bacterial skin and skin structure infections; Treatment of community acquired bacterial pneumonia; Treatment of subjects having bacterial skin or skin structure infection; Treatment of ba...
NUZYRA's oppositions filed in EPO
Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326696 | PARATEK PHARMS | Amino-methyl substituted tetracycline compounds |
Sep, 2023
(2 years ago) | |
| US7553828 | PARATEK PHARMS | 9-aminomethyl substituted minocycline compounds |
Jun, 2025
(7 months ago) | |
| US8383610 | PARATEK PHARMS | Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline |
Sep, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9365500 | PARATEK PHARMS | 9-aminomethyl substituted minocycline compounds |
Jun, 2021
(4 years ago) | |
| US10383884 | PARATEK PHARMS | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(11 years from now) | |
| US9724358 | PARATEK PHARMS | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| US10111890 | PARATEK PHARMS | 9-aminomethyl minocycline compounds and uses thereof |
Aug, 2037
(11 years from now) | |
| US10124014 | PARATEK PHARMS | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| US10835542 | PARATEK PHARMS | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(11 years from now) | |
| US9265740 | PARATEK PHARMS | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| US9314475 | PARATEK PHARMS | Oral and injectable formulations of tetracycline compounds |
Mar, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 02, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Oct 02, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 03 October, 2027
Market Authorisation Date: 02 October, 2018
Dosage: TABLET; POWDER
More Information on Dosage
NUZYRA family patents
6. Spectracef patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5958915 | VANSEN PHARMA | Antibacterial composition for oral administration |
Oct, 2016
(9 years ago) | |
Drugs and Companies using CEFDITOREN PIVOXIL ingredient
Market Authorisation Date: 29 August, 2001
Dosage: TABLET
More Information on Dosage
SPECTRACEF family patents
7. Xenleta patent expiration
Treatment: Treatment of adults with community-acquired bacterial pneumonia caused by susceptible microorganisms
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6753445 | HONG KONG | Pleuromutilin derivatives having antibacterial activity |
Jul, 2021
(4 years ago) | |
| US8071643 | HONG KONG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Mar, 2033
(7 years from now) | |
| US8153689 | HONG KONG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Mar, 2028
(2 years from now) | |
| US9120727 | HONG KONG | Process for the preparation of pleuromutilins |
May, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12121582 | HONG KONG | Injectable pharmaceutical formulations of lefamulin |
Jun, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 19, 2029 |
Drugs and Companies using LEFAMULIN ACETATE ingredient
NCE-1 date: 19 August, 2028
Market Authorisation Date: 19 August, 2019
Dosage: TABLET; SOLUTION
More Information on Dosage
XENLETA family patents